Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Emcure Pharmaceuticals has released its Q4 and FY26 results, marking its first year of a five-year strategic roadmap with strong performance. The company crossed the US$1 billion revenue milestone, achieving 16.6% revenue growth (above guidance) with FY26 revenue of ₹9,204 crore. EBITDA margin expanded by 83 basis points to 19.4%, while adjusted PAT grew over 40% to ₹1,008 crore. International business drove growth with 22% YoY revenue increase, contributing 60% of Q4 revenue, led by emerging markets, Europe, and Canada. Key highlights include Amphotericin B launch, biosimilar Bevacizumab endorsement, and new partnerships with Novo Nordisk, Sanofi, and Roche.
The strong results beat guidance on both revenue and margins, indicating effective execution of the strategic plan. The margin expansion despite higher R&D investment signals operational efficiency gains. New product launches and partnerships provide multi-year growth visibility.